Showing results (1-10 of 104) with videos related to
Sort By:
Pageof 11
Pathologie-Biologie|June 28, 2002
[Prognostic factors in myelodysplasia syndromes]Pierre Fenaux, Stéphane de BottonClinical Lymphoma, Myeloma & Leukemia|July 1, 2021
SOHO State of the Art Updates and Next Questions: IDH InhibitionMatteo Dragani, Stéphane de BottonBest Practice & Research. Clinical Haematology|August 26, 2003
Treatment of older adults with acute promyelocytic leukaemiaPierre Fenaux, Sylvie Chevret, Stéphane de BottonJournal of Blood Medicine|September 14, 2016
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesJohanna Mondesir, Christophe Willekens, Mehdi Touat, et al.Bulletin Du Cancer|March 24, 2011
[Therapy-related acute myeloid leukemia: role of DNA repair]Romain Guièze, Aurélie Ravinet, Eric Hermet, et al.Journal of Clinical Medicine|November 14, 2023
CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic LeukemiaKhalil Saleh, Florence Pasquier, Camille Bigenwald, et al.American Journal of Hematology|February 24, 2021
Differentiation syndrome with lower-intensity treatments for acute myeloid leukemiaAmir T Fathi, Eytan M Stein, Courtney D DiNardo, et al.Journal of Molecular Medicine (Berlin, Germany)|September 25, 2007
Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the differenceNathalie Chaput, Stéphane De Botton, Michel Obeid, et al.Biochemical Pharmacology|July 12, 2008
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparisonSimone Boehrer, Lionel Adès, Lorenzo Galluzzi, et al.Leukemia Research|May 24, 2015
Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogeneticsDelphine Lebon, François Vergez, Sarah Bertoli, et al.Pageof 11